AHAlan E. C. Holden

Alan E. C. Holden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alan E. C. Holden has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Amelie G. Ramirez

    Department of Population Health Sciences, Institute for Health Promotion Research, Long School of Medicine, Mays Cancer Center, University of Texas Health Science Center at San Antonio , San Antonio, TX

    1 shared publication
  • Andrea R. Thurman

    From the *Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, Texas; †Transnational Family Research Institute, Aptos, California; ‡National Institutes of Health, Bethesda, Maryland; §Department of Microbiology, University of Texas Health Science Center, San Antonio; and ¶Department of Biostatistics, Informatics and Epidemiology, Medical University of South Carolina, South Carolina

    1 shared publication
  • Anna M. Nápoles-Springer

    Division of General Internal Medicine, Medical Effectiveness Research Center for Diverse Populations, Department of Medicine, University of California, San Francisco, CA, USA

    1 shared publication
  • Dorothy Long Parma

    Institute for Health Promotion Research, University of Texas Health—San Antonio, 7411 John Smith Drive, Suite 1000, San Antonio, TX 78229, USA

    1 shared publication
  • Edgar Muñoz

    University of Texas , Health Science Center San Antonio, Texas, USA

    1 shared publication
  • Eliseo J. Pérez Stable

    Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland

    1 shared publication

Latest Publications

  • Open Access

    Time to definitive diagnosis of breast cancer in Latina and non-Hispanic white women: the six cities study

    by Amelie G Ramirez, Eliseo J Pérez-Stable, Gregory A Talavera, Frank J Penedo, J Emilio Carrillo, Maria E Fernandez, Edgar Muñoz, Dorothy Long Parma, Alan Ec Holden, Sandra San Miguel de Majors, et al.

    Time delay after an abnormal screening mammogram may have a critical impact on tumor size, stage at diagnosis, treatment, prognosis, and survival of subsequent breast cancer. This study was undertaken to evaluate disparities between Latina and non-Hispanic white (NHW) women in time to definitive diagnosis of breast cancer after an abnormal screening mammogram, as well as factors contributing to such disparities. As part of the activities of the National Cancer Institute (NCI)-funded Redes En Acción research network, clinical records of 186 Latinas and 74 NHWs who received abnormal screening mammogram results were reviewed to determine the time to obtain a definitive diagnosis. Data was obtained from participating clinics in six U.S. cities and included demographics, clinical history, and mammogram characteristics. Kaplan-Meier estimates and Cox proportional hazards models were used to test differences in median time to definitive diagnosis by ethnicity after adjusting for clinic site, demographics, and clinical characteristics. Time-to-event analysis showed that Latinas took 2.2 times longer to reach 50% definitively diagnosed with breast cancer relative to NHWs, and three times longer to reach 80% diagnosed (p=0.001). Latinas’ median time to definitive diagnosis was 60 days compared to 27 for NHWs, a 59% gap in diagnosis rates (adjusted Hazard Ratio [aHR] = 1.59, 95% CI = 1.09, 2.31; p=0.015). BI-RADS-4/5 women’s diagnosis rate was more than twice that of BI-RADS-3 (aHR = 2.11, 95% CI = 1.18, 3.78; p=0.011). Disparities in time between receipt of abnormal screening result and definitive diagnosis adversely affect Latinas compared to NHWs, and remain significant after adjusting for demographic and clinical variables. With cancer now the leading cause of mortality among Latinos, a greater need exists for ethnically and culturally appropriate interventions like patient navigation to facilitate Latinas’ successful entry into, and progression through, the cancer care system.


  • The Influence of Depression on Sexual Risk Reduction and STD Infection in a Controlled, Randomized Intervention Trial

    by Alan E. C. Holden, Rochelle N. Shain, Warren B. Miller, Jeanna M. Piper, Sondra T. DrPH Perdue, Andrea R. Thurman, Jeffrey E. Korte

    Background: A randomized controlled trial of SAFE, a cognitive/behavioral intervention, revealed that it significantly reduces reinfection and behavioral risks among participants compared with controls. However, studies suggest that depression may moderate intervention efficacy among affected persons because of impaired information processing, failure to recognize risk, or inability to change behavior. Goal: We evaluated SAFE efficacy among depressed and nondepressed Mexican- and African American women after comparing initial risk factors by depression status. We further explored intervention effects in moderately and severely depressed women. Study Design: We stratified 477 participants (249 intervention, 228 controls) according to their depression status at baseline determined by CES-D scores. Using χ2 and multivariate logistic regression, we evaluated differences in reinfection and behavioral risk at 6-month, 12-month, and 1-year cumulative follow-ups between groups within baseline depression strata. Results: At baseline, 74.4% of women were depressed and had significantly greater levels of behavioral risks than nondepressed women. At follow-up intervals, behavioral risks and reinfection rates were lower among intervention women compared with controls regardless of depression status. For example, at 1-year follow-up reinfection rates were 15.2% in nondepressed intervention women versus 21.4% in nondepressed controls (AOR = 0.6), and 18.6% in depressed intervention women versus 27.3% in depressed controls (AOR = 0.6). Moreover, reinfection was consistently lower among moderately and severely depressed intervention women than controls (moderately depressed: 19.3% vs. 27.2%, AOR = 0.6; severely depressed: 17.9% vs. 27.5%, AOR = 0.6). Conclusions: Despite significantly greater behavioral risk among depressed women at baseline, SAFE was equally successful in reducing reinfection and high-risk behavior among depressed and nondepressed participants.